Inactive Instrument

Highlights Bio-Path Holdings Inc Nasdaq

Equities

US09057N2018

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Bio-Path Closes $1.2 Million Share Offering	04-19	MT
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	04-18	CI
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	04-15	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Reverse Split: 1 of 20	02-22	FA
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	01-10	CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia	12-14	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia	01/08/23	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
North American Morning Briefing : Traders Await -3-	31/03/23	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Bio-Path Holdings, Inc. Provides Clinical and Operational Update	16/03/23	CI
Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors	07/12/22	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	24/10/22	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bio-Path Holdings Inc Nasdaq

Equities

US09057N2018

Highlights

Filters